Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib resistance, 2 second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed. To predict potential side effects and novel medical uses, we generated comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs. Our studies yielded 4 major findings: (1) The interaction profiles of the 3 drugs displayed strong differences and only a small overlap covering the ABL kinases. (2) Dasatinib bound in excess of 30 Tyr and Ser/Thr kinases, including major regulators of the immune system, suggesting that dasatinib might have a particular impact on immune function. (3) Despite the high specificity of nilotinib, the receptor tyrosine kinase DDR1 was identified and validated as an additional major target. (4) The oxidoreductase NQO2 was bound and inhibited by imatinib and nilotinib at physiologically relevant drug concentrations, representing the first nonkinase target of these drugs.

[1]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[2]  K. Bhalla,et al.  A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy. , 2006 .

[3]  D. Jamieson,et al.  Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor , 2006, British Journal of Cancer.

[4]  C. Sawyers,et al.  Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias , 2003, Oncogene.

[5]  M. Zucchetti,et al.  α1 Acid Glycoprotein Binds to Imatinib (STI571) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients , 2003 .

[6]  Margaret Gardiner-Garden,et al.  Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer , 2004, Clinical Cancer Research.

[7]  G. Superti-Furga,et al.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.

[8]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[9]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[10]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[11]  W. Rutter,et al.  A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Nikolich,et al.  Discoidin Domain Receptor-1a (DDR1a) Promotes Glioma Cell Invasion and Adhesion in Association with Matrix Metalloproteinase-2 , 2006, Journal of Neuro-Oncology.

[13]  M. Nau,et al.  Regulating the regulator: negative regulation of Cbl ubiquitin ligases. , 2006, Trends in biochemical sciences.

[14]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[15]  M. Zucchetti,et al.  Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[17]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[18]  Bernhard Kuster,et al.  Profiling Core Proteomes of Human Cell Lines by One-dimensional PAGE and Liquid Chromatography-Tandem Mass Spectrometry*S , 2003, Molecular & Cellular Proteomics.

[19]  K. Arimura,et al.  Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. , 2005, American journal of respiratory cell and molecular biology.

[20]  R. Kurzrock,et al.  Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. , 1987, Cancer research.

[21]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[22]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Fabbro,et al.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.

[24]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[25]  Jessica M. Lindvall,et al.  Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling , 2005, Immunological reviews.

[26]  H. Kantarjian,et al.  The biology of chronic myelogenous leukemia: implications for imatinib therapy. , 2007, Seminars in hematology.

[27]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[28]  J. Mestan,et al.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL , 2006, British Journal of Cancer.

[29]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[31]  Zhongtao Zhang,et al.  Crystal structure of quinone reductase 2 in complex with resveratrol. , 2004, Biochemistry.

[32]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[33]  W. Farrar,et al.  Activation of Discoidin Domain Receptor 1 Isoform b with Collagen Up-Regulates Chemokine Production in Human Macrophages: Role of p38 Mitogen-Activated Protein Kinase and NF-κB , 2004, The Journal of Immunology.

[34]  K. Legate,et al.  ILK, PINCH and parvin: the tIPP of integrin signalling , 2006, Nature Reviews Molecular Cell Biology.

[35]  L. Meijer,et al.  Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography , 2007, Biotechnology journal.

[36]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[37]  H. Kantarjian,et al.  Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI). , 2006 .

[38]  G. Ferry,et al.  NRH:quinone reductase 2: an enzyme of surprises and mysteries. , 2005, Biochemical pharmacology.

[39]  M. Vihinen,et al.  Lindvall, J. M. et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203, 200-215 , 2005 .

[40]  B. Druker.  Circumventing resistance to kinase-inhibitor therapy. , 2006, The New England journal of medicine.

[41]  H. Daub.  Characterisation of kinase-selective inhibitors by chemical proteomics. , 2005, Biochimica et biophysica acta.

[42]  T. Suda,et al.  Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. , 2001, The European respiratory journal.

[43]  Y. Natkunam,et al.  The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. , 2006, Haematologica.

[44]  References , 1971 .

[45]  J Mottram,et al.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.

[46]  L. Amzel,et al.  Crystal structure of human quinone reductase type 2, a metalloflavoprotein. , 1999, Biochemistry.

[47]  E. Nishida,et al.  Identification and Characterization of a Novel MAP Kinase Kinase Kinase, MLTK* , 2001, The Journal of Biological Chemistry.

[48]  Jürgen Drews,et al.  Case histories, magic bullets and the state of drug discovery , 2006, Nature Reviews Drug Discovery.

[49]  N. Donato,et al.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.